Showing results (201-210 of 296) with videos related to
Sort By:
Pageof 30
Journal of Inherited Metabolic Disease|July 20, 2024
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registryDerralynn A Hughes, Gere Sunder-Plassmann, Ana Jovanovic, et al.Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.JACC. Cardiovascular Interventions|February 11, 2026
Major Bleeding Risk Assessment With Atrial Fibrillation Post-TAVR: The HARHP Score Results From ENVISAGE-TAVI AFGeorge D Dangas, Martin Unverdorben, Christian Hengstenberg, et al.Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.Journal of Molecular Medicine (Berlin, Germany)|October 8, 2018
Nuclear calcineurin is a sensor for detecting Ca2+ release from the nuclear envelope via IP3RSilvana Olivares-Florez, Martin Czolbe, Fabian Riediger, et al.Circulation|March 1, 2006
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarctionMatthias Nahrendorf, Kai Hu, Stefan Frantz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.Pageof 30